Mixed results for Phase III trial of Pfizer's investigational Clostridioides difficile vaccine

2 March 2022
pfizer_big

In an area where big pharma has failed to find success, US pharma giant Pfizer (NYSE: PFE) has joined the ranks, on Tuesday announcing mixed results from the CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial), a pivotal Phase III study evaluating its Clostridioides difficile (C. difficile) vaccine candidate (PF-06425090) in the prevention of C. difficile infection (CDI).

Initial analyses of two protocol defined secondary endpoints indicated a highly favorable benefit in reducing CDI severity and 100% vaccine efficacy in preventing medically attended CDI, although the trial did not meet its pre-specified primary endpoint of prevention of primary CDI. Safety reviews indicated that the investigational vaccine was safe and well tolerated.

The Pfizer vaccine had been the frontrunner in the C. difficile space following a 2017 decision by French drug major Sanofi (Euronext: SAN) to abandon its trial, which was on track to become the first option available globally for the prevention of C. difficile, and GlobalData analysts estimated at the time said could have reached $400 million in peak sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical